We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Dental Implant Therapy on a Patient With von Willebrand Disease: A Case Study.
Implant Dentistry 2018 October
BACKGROUND: Von Willebrand disease (vWD) is the most common hereditary disorder affecting coagulation. Patients with this disorder are at a higher risk of postoperative complications after dental surgery. This article discusses the successful treatment for a patient with vWD undergoing implant therapy.
CASE DESCRIPTION: A young 21-year-old patient with vWD lost tooth #30 because of caries and required implant therapy. Through collaboration with a hematologist administering prophylactic desmopressin (DDAVP), the implant surgery was performed without any postoperative complications. The implant successfully integrated and was restored into function. The successful outcome met expectations after careful planning and execution.
PRACTICAL IMPLICATIONS: Collaboration with the appropriate medical providers, as well as treatment modifications for surgical procedures during implant therapy, is necessary for successful treatment of a patient with von Willebrand disorder.
CASE DESCRIPTION: A young 21-year-old patient with vWD lost tooth #30 because of caries and required implant therapy. Through collaboration with a hematologist administering prophylactic desmopressin (DDAVP), the implant surgery was performed without any postoperative complications. The implant successfully integrated and was restored into function. The successful outcome met expectations after careful planning and execution.
PRACTICAL IMPLICATIONS: Collaboration with the appropriate medical providers, as well as treatment modifications for surgical procedures during implant therapy, is necessary for successful treatment of a patient with von Willebrand disorder.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app